Oncology Reviews最新文献_第2页

METTL1 in human cancers: recognition of their functions, mechanisms and therapeutic value. METTL1在人类癌症中的作用、机制和治疗价值

IF 5.2

Oncology Reviews Pub Date : 2025-07-30 eCollection Date: 2025-01-01 DOI: 10.3389/or.2025.1637372

Xinyu Zhang, Yuan Chen, Min Li, Xiaomeng Zhou, Qingcui Song

引用次数: 0

Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach. 激素敏感性前列腺癌的三重系统治疗：多学科方法的重要回顾。

IF 5.2

Oncology Reviews Pub Date : 2025-07-25 eCollection Date: 2025-01-01 DOI: 10.3389/or.2025.1599292

Almudena Zapatero, Teresa Alonso-Gordoa, Alfredo Rodríguez Antolín, Felipe Couñago, Noelia Sanmamed, Mario Domínguez Esteban, Marta López Valcárcel, Ray Manneh, Ángel Borque-Fernando, Nuria Sala González, Pablo Maroto

{"title":"Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach.","authors":"Almudena Zapatero, Teresa Alonso-Gordoa, Alfredo Rodríguez Antolín, Felipe Couñago, Noelia Sanmamed, Mario Domínguez Esteban, Marta López Valcárcel, Ray Manneh, Ángel Borque-Fernando, Nuria Sala González, Pablo Maroto","doi":"10.3389/or.2025.1599292","DOIUrl":"10.3389/or.2025.1599292","url":null,"abstract":"This article aims to critically evaluate the evidence for triplet therapy consisting of androgen deprivation therapy (ADT), docetaxel and a second-generation androgen receptor pathway inhibitor ([ARPI]; abiraterone, enzalutamide, darolutamide or apalutamide) in patients with metastatic hormone-sensitive prostate cancer (mHSPC), and what this evidence reveals regarding the use of these treatments in clinical practice. A search of PubMed, Medline, Embase, Cochrane, Scopus and Web of Science was conducted in April 2024 to identify relevant prospective and retrospective observational trials, randomized controlled trials (RCTs) and meta-analyses. The search identified 52 relevant articles: six full articles and 31 abstracts based on three RCTs, one observational study and 14 meta-analyses. Abiraterone- or darolutamide-containing triplet therapy was significantly better than ADT + docetaxel for improving overall survival in all study populations, particularly subgroups with high-volume and/or synchronous disease. The tolerability of ADT + docetaxel and triplet therapy were similar with most adverse events related to docetaxel. There were no data comparing triplet therapy with ADT + ARPI doublet therapy. Triplet therapy appears to be the most effective first-line regimen for men with mHSPC, good performance status and high-volume and synchronous metastases. Darolutamide-based triplet therapy may also be of benefit in other patients with high- or low-risk disease. Careful consideration of the risks and benefits are required to determine which patients can be spared from receiving docetaxel and rather be treated with alternative regimens.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"19 ","pages":"1599292"},"PeriodicalIF":5.2,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12331671/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genetic counseling for hereditary cancer syndromes: a 5-year experience from a single center in Bulgaria. 遗传性癌症综合征的遗传咨询：保加利亚单一中心的5年经验。

IF 5.2

Oncology Reviews Pub Date : 2025-07-25 eCollection Date: 2025-01-01 DOI: 10.3389/or.2025.1605606

Mari Hachmeriyan, Mariya Levkova, Dinnar Yahya, Milena Stoyanova, Eleonora Dimitrova

{"title":"Genetic counseling for hereditary cancer syndromes: a 5-year experience from a single center in Bulgaria.","authors":"Mari Hachmeriyan, Mariya Levkova, Dinnar Yahya, Milena Stoyanova, Eleonora Dimitrova","doi":"10.3389/or.2025.1605606","DOIUrl":"10.3389/or.2025.1605606","url":null,"abstract":"This study presents a 5-year retrospective analysis of genetic counseling (GC) services for hereditary cancer syndromes (HCS) at a single center in Bulgaria. The aim is to describe the demographic and epidemiological characteristics of patients seeking GC, the uptake of genetic testing, and the spectrum of identified pathogenic variants. The results highlight an increasing trend in GC utilization. Key findings include differences in patient profiles between those seeking general HCS assessment and those undergoing tumor biomarker testing, the impact of financial accessibility on genetic testing uptake, and a pathogenic variant detection rate of 28% in tested individuals. The most frequently identified conditions were Hereditary Breast and Ovarian Cancer Syndrome and Lynch Syndrome, with pathogenic variants detected in genes such as BRCA1, MSH2, PALB2, and STK11. These findings underscore the need for enhanced awareness, improved financial access to testing, and the establishment of systematic cascade screening programs in Bulgaria.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"19 ","pages":"1605606"},"PeriodicalIF":5.2,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12331608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mitophagy in the mechanisms of treatment resistance in solid tumors. 实体瘤耐药机制中的线粒体自噬。

IF 5.2

Oncology Reviews Pub Date : 2025-07-21 eCollection Date: 2025-01-01 DOI: 10.3389/or.2025.1607983

Xiaoyi Yan, Hui Ding, Mengxiao Ren, Lei Zang

引用次数: 0

Fibroblast activation protein and the tumour microenvironment: challenges and therapeutic opportunities. 成纤维细胞活化蛋白和肿瘤微环境：挑战和治疗机会。

IF 5.2

Oncology Reviews Pub Date : 2025-07-16 eCollection Date: 2025-01-01 DOI: 10.3389/or.2025.1617487

Hsing Hwa Lee, Zeyad Al-Ogaili

引用次数: 0

The role and research progress of the MET signalling pathway in targeted therapy for osteosarcoma. MET信号通路在骨肉瘤靶向治疗中的作用及研究进展。

IF 3.1

Oncology Reviews Pub Date : 2025-06-17 eCollection Date: 2025-01-01 DOI: 10.3389/or.2025.1615111

Qilong Su, Jingyu Hou, Xinhui Du, Fan Zhang, Panhong Zhang, Bangmin Wang, Weitao Yao

{"title":"The role and research progress of the MET signalling pathway in targeted therapy for osteosarcoma.","authors":"Qilong Su, Jingyu Hou, Xinhui Du, Fan Zhang, Panhong Zhang, Bangmin Wang, Weitao Yao","doi":"10.3389/or.2025.1615111","DOIUrl":"10.3389/or.2025.1615111","url":null,"abstract":"MET, a receptor tyrosine kinase proto-oncogene and the specific receptor for hepatocyte growth factor (HGF), plays a critical role in the initiation and progression of osteosarcoma (OS) through sustained pathway activation. Aberrant activation of MET has been shown to trigger multiple downstream signalling pathways, including RAS-ERK, PI3K-AKT, and STAT3, which are essential for OS cell proliferation, invasion, differentiation, and drug resistance. In recent years, significant progress has been made in the development of small-molecule inhibitors and specific antibodies targeting MET for OS therapy. The use of combination therapy as a treatment strategy involves the use of MET inhibitors in conjunction with chemotherapy, immunotherapy, and other targeted therapies. This approach has the potential to overcome resistance and improve therapeutic efficacy. This review summarises the mechanisms of MET signalling in OS, with a focus on the progress of MET-targeted therapies and their combination with other therapeutic strategies. The study provides valuable insights into future research directions, offering novel perspectives on the role of MET as a therapeutic target in OS.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"19 ","pages":"1615111"},"PeriodicalIF":3.1,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12209371/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144541632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Colorectal cancer in south sulawesi: a case-control study for nongenetic risk factors. 南苏拉威西的结直肠癌：非遗传危险因素的病例对照研究。

IF 3.1

Oncology Reviews Pub Date : 2025-05-30 eCollection Date: 2025-01-01 DOI: 10.3389/or.2025.1589655

Upik A Miskad, Matthew Martianus Henry, Carissa Ikka Pardamean, Arif Budiarto, Akram Irwan, James W Baurley, Irawan Yusuf, Bens Pardamean

{"title":"Colorectal cancer in south sulawesi: a case-control study for nongenetic risk factors.","authors":"Upik A Miskad, Matthew Martianus Henry, Carissa Ikka Pardamean, Arif Budiarto, Akram Irwan, James W Baurley, Irawan Yusuf, Bens Pardamean","doi":"10.3389/or.2025.1589655","DOIUrl":"10.3389/or.2025.1589655","url":null,"abstract":"Background: This study analyzed the nongenetic risk factors that contributed to colorectal cancer (CRC) incidence in the South Sulawesi population through a case-control study.Methods: The sample consisted of 89 cases and 84 controls, aged between 19-86, with 99 males and 74 females from different ethnic groups. Univariate analysis was carried out using chi-square, Fisher's exact test, <math><mrow><mi>t</mi></mrow> </math> -test, and Mann-Whitney U test. Significant nongenetic risk factors were selected through the logit model L1 regularization, adjusted for age, gender, and ethnicity. The analyzed risk factors were the patient's weight, height, body mass index (BMI), defecation location, exercise habit, smoking habit, marital status, occupation, education level, and distance to the nearest health center. The estimated odds ratio from the logit model was used to analyze the significance of the selected risk factors.Results: The significant risk factors from the logit model were smoking habit, education level, marital status, distance to the nearest health center, and weight. CRC cases were more likely to have lower education (OR = 1.819, 95% CI 1.354-2.443), residing in remote areas (OR = 1.44, 95% CI 1.17-1.772), experiencing decreasing weight (OR = 1.03, 95% CI 1.013-1.048). Controls were more likely to be non-smokers (OR = 0.325, 95% CI 0.149-0.707) and unmarried (OR = 0.161, 95% CI 0.036-0.716).Conclusion: The study determined that other nongenetic risk factors, including education level, distance to the nearest health center, weight, smoking habit, and marital status, contributed to the CRC incidence within the South Sulawesi population. The study emphasized the importance in accounting for these risk factors for further, targeted CRC preventions.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"19 ","pages":"1589655"},"PeriodicalIF":3.1,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12162515/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144302521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A brief review of Lynch syndrome: understanding the dual cancer risk between endometrial and colorectal cancer. 简要回顾Lynch综合征：了解子宫内膜癌和结直肠癌之间的双重癌症风险。

IF 3.1

Oncology Reviews Pub Date : 2025-05-16 eCollection Date: 2025-01-01 DOI: 10.3389/or.2025.1549416

Sneha Pallatt, Sibin Nambidi, Subhamay Adhikary, Antara Banerjee, Surajit Pathak, Asim K Duttaroy

{"title":"A brief review of Lynch syndrome: understanding the dual cancer risk between endometrial and colorectal cancer.","authors":"Sneha Pallatt, Sibin Nambidi, Subhamay Adhikary, Antara Banerjee, Surajit Pathak, Asim K Duttaroy","doi":"10.3389/or.2025.1549416","DOIUrl":"10.3389/or.2025.1549416","url":null,"abstract":"Lynch syndrome (LS) is an autosomal dominant disorder caused by germline mutations in DNA mismatch repair (MMR) genes. These mutations result in frameshift alterations, leading to the accumulation of errors within microsatellites. Individuals with LS have an elevated risk of developing colorectal and distant malignancies, including endometrial cancer (EC), which is one of the most common cancer associated with LS. Despite its significance, the association between EC and LS is often underexplored. Given the slow progression of colorectal cancer (CRC), there is an opportunity for early detection and intervention, which can aid in reducing both incidence and mortality through the identification and management of pre-malignant lesions and early-stage tumors in colorectum/endometrium. Recognizing individuals with a heightened risk of CRC is essential for implementing personalized screening strategies. This review summarizes the original research work on LS to find out the correlation of CRC following an endometrial cancer diagnosis in individuals with MMR gene mutations, may involve refine treatment strategies and moreover this review may help clinicians and researchers to get an up-to date information on LS and its advanced treatment possibilities.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"19 ","pages":"1549416"},"PeriodicalIF":3.1,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12122774/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of UGT1A1 polymorphism in the management of colorectal cancer. UGT1A1多态性在结直肠癌治疗中的作用

IF 3.1

Oncology Reviews Pub Date : 2025-05-13 eCollection Date: 2025-01-01 DOI: 10.3389/or.2025.1547904

Elham Babadi, Kamran Roudini, Kianmehr Aalipour, Olatunji B Alese

{"title":"The role of UGT1A1 polymorphism in the management of colorectal cancer.","authors":"Elham Babadi, Kamran Roudini, Kianmehr Aalipour, Olatunji B Alese","doi":"10.3389/or.2025.1547904","DOIUrl":"10.3389/or.2025.1547904","url":null,"abstract":"Colorectal cancer is a leading cause of cancer related deaths among patients worldwide, necessitating the development of more effective and tolerable therapies. Topoisomerase I inhibitors such as Irinotecan are integral components of chemotherapy regimens used in the management of colorectal, as well as esophageal, gastric, biliary tract, pancreatic, neuroendocrine, small bowel and anal carcinomas. Efficacy and toxicity of these regimens are however impacted by metabolism via the UGT1A1 pathways. This literature review provides a comprehensive overview of UGT1A1 polymorphism in patients with colorectal cancer, including recent developments and the future landscape. Recent literature elucidating the roles of oncogenes and predictive biomarkers on anti-cancer drugs and UGT1A1 genotypes are described. The lack of consensus in the clinical management of patients with colorectal cancer were also explored in depth. A comprehensive search was performed in multiple databases (including PubMed, Embase, Web of Science, Scopus, Research gate, and Google Scholar) to identify relevant articles published up to January 2024. A total of 79 clinical studies were included in this review. The epidemiology and frequency of UGT1A1 genes polymorphisms by race, gender, ethnicity, geographic location and stage of the cancer were correlated with drug metabolism, toxicity, and survival outcomes. The tole of UGT1A1 as a prognostic and predictive biomarker, including existing challenges in clinical application were also discussed extensively.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"19 ","pages":"1547904"},"PeriodicalIF":3.1,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12106485/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144160721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting mitochondrial ClpP: structural insights and therapeutic potential of ClpP agonists in cancer therapy. 靶向线粒体ClpP: ClpP激动剂在癌症治疗中的结构见解和治疗潜力。

IF 3.1

Oncology Reviews Pub Date : 2025-05-06 eCollection Date: 2025-01-01 DOI: 10.3389/or.2025.1567860

Mowei Kong, Yang Yu, Shuai Shao, Chunxiang Zhang

{"title":"Targeting mitochondrial ClpP: structural insights and therapeutic potential of ClpP agonists in cancer therapy.","authors":"Mowei Kong, Yang Yu, Shuai Shao, Chunxiang Zhang","doi":"10.3389/or.2025.1567860","DOIUrl":"10.3389/or.2025.1567860","url":null,"abstract":"Mitochondrial \"powerhouses\" play a central function in cellular metabolism and energy generation. Their dysregulation is directly correlated with a myriad of diseases, among them cancer. The serine protease ClpP, accompanied by its cochaperone ClpX, is a principal homeostatic regulator in mitochondrial function by degrading aberrant proteins in order to preserve mitochondrial integrity. Recently, evidence suggests ClpP is overexpressed in many cancer cells and, as such, is an appealing target for drug therapy. In this review, current information about the structure, physiological function, and therapeutic promise of mitochondrial ClpP in oncology is summarized. We provide an overview about the mechanistic rationale behind ClpP agonists as novel anticancer drugs, their regulation in cell signal transduction, and the major challenge in the creation of small molecules that specifically activate human ClpP, but not bacterial ClpP. The review highlights the therapeutic promise of ClpP agonists as a novel approach in cancer therapy, presenting their prospective potential for cancer treatment by focusing on an unexplored mitochondrial target.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"19 ","pages":"1567860"},"PeriodicalIF":3.1,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12089087/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144111491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0